( dies including more than 17000womenb...)Gardasil Demonstrates Up to 100% Efficacy,Health

dies, including more than 17,000 womenb),c), Gardasil® provided benefits against pre-cancerous (CIN2/3) and potentially pre-cancerous cervical lesions (CIN1) caused by additional virus types not directly targeted by the vaccine. The additional virus types cause more than 10% of cervical cancer and substantial proportions of pre-cancerous and potentially pre-cancerous cervical lesions. The data have recently been submitted to the European Medicines Agency (EMEA) and the US Food and Drug Administration in order to update the marketing authorisation for Gardasil®.

The burden of cervical cancer and other Human Papillomavirus diseases
Despite screening for early detection, cervical cancer remains the second most common cause of death from cancer (after breast cancer) among young women (15-44 years) in Europe . Around 33,500 women are diagnosed with, and 15,000 women die from cervical cancer each year (the equivalent of 40 women per day or nearly 2 per hour).
In addition, hundreds of thousands of women are diagnosed with other Human Papillomavirus diseases that start before cervical cancer and go beyond the cervix. These diseases include pre-cancerous and potentially pre-cancerous cervical lesions7,9, , vulvar and vaginal cancer5,6, , pre-cancerous vulvar and vaginal lesions10,11, , and genital warts.
Cervical cancer is caused by Human Papillomavirus. , The virus is very common, with 70% of sexually active people estimated to become exposed at some point in life. , , Genital infections with Human Papillomavirus are very common with the majority of infections occurring in adolescence or early adulthood. ,

EU indication of Gardasil®
According to the licence in the EU, Gardasil®, Human Papillomavirus Vaccine [types 6,11,16,18] (Recombinant, adsorbed), can be given to children and adolescents 9 to15 years and adult females 16 to 26 years of age and is indicated for the prevention of cervical carcinoma (cervic
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
2. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer